The NISCH Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from Raji B-lymphoblastoid cells, designed for targeted disruption of the NISCH gene. NISCH encodes nischarin, a scaffolding protein with tumor-suppressive and anti-migratory functions. The knockout model provides a loss-of-function system to investigate nischarin-dependent regulation of integrin and insulin receptor signaling in a B-cell context.
Raji cells originate from a Burkitt??s lymphoma patient and represent an Epstein-Barr virus (EBV)-positive B lymphocyte line. These cells retain key B-cell properties, including antigen presentation and immunoglobulin expression, and are widely used to study lymphomagenesis, immune cell adhesion, and signal transduction. The EBV-driven immortalization maintains an active integrin profile and a recognizable cytoskeletal architecture suitable for migration and adhesion assays.
Nischarin acts as a scaffold that integrates signals from integrin ??5 (ITGA5) and insulin/IGF-1 receptors. It directly binds ITGA5 and insulin receptor substrate 4 (IRS-4), thereby inhibiting the Rac1/PAK1/LIMK pathway and suppressing cofilin-mediated actin remodeling. This limits lamellipodial protrusion and cell motility. Concurrently, nischarin activates AMPK and modulates PI3K/AKT signaling downstream of insulin receptor, creating a node that coordinates metabolic and cytoskeletal responses.
In Raji B lymphocytes, ablation of NISCH eliminates nischarin??s inhibitory interactions with ITGA5 and IRS-4, releasing Rac1/PAK1-driven motility and potentially enhancing chemotactic responses. Altered integrin signaling may affect B-cell homing and immune surveillance functions, while disrupted insulin/IGF-1 pathway modulation could shift metabolic programs. This polyclonal knockout population thus serves as a relevant model for probing nischarin??s role in lymphoma cell dissemination and metabolic regulation.
This knockout tool is applicable to cancer biology, metastasis research, and metabolic signaling studies. Researchers can validate nischarin depletion by Western blotting, assess migration via Transwell assays, and measure Rac1 activation status. Co-immunoprecipitation of nischarin complexes, flow cytometry for ITGA5 surface expression, and immunofluorescence for F-actin architecture further support detailed pathway analysis. Xenograft models may explore tumor growth and metastasis. For further details, please contact Ascent Research.
